N4 Pharma PLC Broker Offer to raise a maximum of GBP1 million (8282G)
18 Noviembre 2022 - 1:01AM
UK Regulatory
TIDMN4P
RNS Number : 8282G
N4 Pharma PLC
18 November 2022
18 November 2022
N4 Pharma plc
("N4 Pharma" or the "Company")
Broker Offer to raise a maximum of GBP1 million
-- N4 Pharma (AIM: N4P) announces a Broker Offer through Turner
Pope Investments (TPI) Limited ("TPI")
-- The Issue Price of the Broker Offer is 2 pence per new ordinary share
-- Existing Shareholders or other interested parties who wish to
register their interest in participating in the Broker Offer should
click on the following TPI platform link: N4 Pharma Broker
Offer
-- The Broker Offer has an initial expected value of GBP0.25
million but may be extended, with the express agreement of the
Company, to GBP1.0 million in the event the Broker Offer is
oversubscribed
-- All bids communicated to TPI under the Broker Offer are
subject to review and acceptance by the Company and TPI and
priority will be given to existing shareholders in the event of
oversubscription
-- The Broker Offer remains open until 4:30 p.m. on Monday, 21 November 2022
Broker Offer through TPI
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, wishes to provide an opportunity for shareholders and
other investors who did not participate in the fundraising
announced today to invest in the Company.
Under the Placing Agreement, TPI has been granted an option in
the form of a broker offer ("Broker Offer") under which TPI will,
as agent for the Company, invite subscriptions for additional new
ordinary shares of 0.4p each in the Company ("Broker Offer Shares")
with an initial expected value of GBP0.25 million at the issue
price of 2p ("Issue Price"). The Broker Offer may be extended, with
the express agreement of the Company, to GBP1.0 million in the
event the Broker Offer is oversubscribed. Accordingly, the maximum
number of Broker Offer Shares to be issued under the Broker Offer
at the Issue Price is 50,000,000.
The Broker Offer opens immediately and will close at 4.30pm on
Monday, 21 November 2022.
As far as is practical, participation in the Broker Offer will
be prioritised for shareholders (direct or indirect) on the
register at the close of business on 17 November 2022 ("Existing
Shareholders").
To subscribe for Broker Offer Shares, Existing Shareholders or
other interested parties who wish to register their interest in
participating in the Broker Offer should click on the following
link : N4 Pharma Broker Offer
A further announcement will be made following the end of the
period during which the Broker Offer is open. If the Broker Offer
is not fully subscribed by 4.30 p.m. on 21 November 2022, orders
from eligible investors will be satisfied in full, and the balance
of the Broker Offer shall lapse.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
James Pope
IFC Advisory Ltd Tel: +44(0)20 3934
6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through preclinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPGMWGUPPGMM
(END) Dow Jones Newswires
November 18, 2022 02:01 ET (07:01 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De May 2023 a May 2024